{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(3)"],"submitter":["Dillard P"],"funding":["Norges Forskningsråd","Helse Sør-Øst RHF"],"pubmed_abstract":["T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel hTERT-specific TCR sequence, named Radium-4, from a clinically responding pancreatic cancer patient vaccinated with a long hTERT peptide. Radium-4 TCR-redirected primary CD4<sup>+</sup> and CD8<sup>+</sup> T cells demonstrated in vitro efficacy, producing inflammatory cytokines and killing hTERT<sup>+</sup> melanoma cells in both 2D and 3D settings, as well as malignant, patient-derived ascites cells. Importantly, T cells expressing Radium-4 TCR displayed no toxicity against bone marrow stem cells or mature hematopoietic cells. Notably, Radium-"],"journal":["Molecular therapy : the journal of the American Society of Gene Therapy"],"pagination":["1199-1213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7934585"],"repository":["biostudies-literature"],"pubmed_title":["Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy."],"pmcid":["PMC7934585"],"pubmed_authors":["Mælandsmo GM","Kvalheim G","Walchli S","Gaudernack G","Pollmann S","Winge-Main A","Florenes VA","Myhre MR","Inderberg EM","Maggadottir SM","Koksal H","Menard M","Dillard P"],"additional_accession":[]},"is_claimable":false,"name":"Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.","description":"T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel hTERT-specific TCR sequence, named Radium-4, from a clinically responding pancreatic cancer patient vaccinated with a long hTERT peptide. Radium-4 TCR-redirected primary CD4<sup>+</sup> and CD8<sup>+</sup> T cells demonstrated in vitro efficacy, producing inflammatory cytokines and killing hTERT<sup>+</sup> melanoma cells in both 2D and 3D settings, as well as malignant, patient-derived ascites cells. Importantly, T cells expressing Radium-4 TCR displayed no toxicity against bone marrow stem cells or mature hematopoietic cells. Notably, Radium-","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-04-08T14:45:31.653Z","creation":"2025-02-19T03:26:54.809Z"},"accession":"S-EPMC7934585","cross_references":{"pubmed":["33212301"],"doi":["10.1016/j.ymthe.2020.11.019"]}}